BG62876B1 - Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост - Google Patents

Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост Download PDF

Info

Publication number
BG62876B1
BG62876B1 BG101803A BG10180397A BG62876B1 BG 62876 B1 BG62876 B1 BG 62876B1 BG 101803 A BG101803 A BG 101803A BG 10180397 A BG10180397 A BG 10180397A BG 62876 B1 BG62876 B1 BG 62876B1
Authority
BG
Bulgaria
Prior art keywords
melatonin
benzodiazepine
treatment
daily
use according
Prior art date
Application number
BG101803A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG101803A (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of BG101803A publication Critical patent/BG101803A/xx
Publication of BG62876B1 publication Critical patent/BG62876B1/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG101803A 1995-02-01 1997-07-30 Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост BG62876B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (2)

Publication Number Publication Date
BG101803A BG101803A (en) 1998-04-30
BG62876B1 true BG62876B1 (bg) 2000-10-31

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101803A BG62876B1 (bg) 1995-02-01 1997-07-30 Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост

Country Status (22)

Country Link
JP (1) JP4516159B2 (fi)
CN (1) CN1083263C (fi)
AT (1) AT408188B (fi)
AU (1) AU695366B2 (fi)
BG (1) BG62876B1 (fi)
BR (1) BR9607169A (fi)
CZ (1) CZ291349B6 (fi)
DK (1) DK176081B1 (fi)
EE (1) EE03384B1 (fi)
FI (1) FI119586B (fi)
IS (1) IS1980B (fi)
LU (1) LU90118B1 (fi)
LV (1) LV11940B (fi)
MD (1) MD1716C2 (fi)
NO (1) NO312814B1 (fi)
NZ (1) NZ298878A (fi)
PL (1) PL183148B1 (fi)
SI (1) SI9620022A (fi)
SK (1) SK284521B6 (fi)
TR (1) TR199700723T1 (fi)
TW (1) TW483757B (fi)
WO (1) WO1996023496A1 (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60034373T2 (de) 2000-01-05 2007-12-20 Neurim Pharmaceuticals (1991) Ltd. Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20180100450A (ko) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
MX2015007909A (es) 2012-12-18 2016-04-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6830156B2 (ja) * 2016-10-31 2021-02-17 ニューリム・ファーマシューティカルズ・リミテッドNeurim Pharmaceuticals Ltd. メラトニンミニタブレットおよびその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
NO973531D0 (no) 1997-07-31
FI119586B (fi) 2009-01-15
TW483757B (en) 2002-04-21
IS4532A (is) 1997-07-25
MD1716B2 (en) 2001-08-31
FI973185A (fi) 1997-09-30
CN1172431A (zh) 1998-02-04
AU4457496A (en) 1996-08-21
NO312814B1 (no) 2002-07-08
SK103097A3 (en) 1998-01-14
DK176081B1 (da) 2006-04-18
MX9705856A (es) 1998-07-31
NO973531L (no) 1997-09-30
TR199700723T1 (xx) 1998-02-21
DK89697A (da) 1997-07-30
SK284521B6 (sk) 2005-05-05
LU90118B1 (fr) 1997-11-13
NZ298878A (en) 1999-05-28
CZ291349B6 (cs) 2003-02-12
WO1996023496A1 (en) 1996-08-08
BG101803A (en) 1998-04-30
MD1716C2 (ro) 2002-02-28
IS1980B (is) 2005-01-14
MD970254A (en) 1999-05-31
JP4516159B2 (ja) 2010-08-04
ATA901396A (de) 2001-02-15
LV11940B (en) 1998-05-20
LV11940A (lv) 1998-01-20
AT408188B (de) 2001-09-25
BR9607169A (pt) 1997-11-11
SI9620022A (sl) 1998-10-31
CZ240597A3 (cs) 1998-01-14
PL183148B1 (pl) 2002-05-31
JPH10513177A (ja) 1998-12-15
EE9700166A (et) 1998-02-16
FI973185A0 (fi) 1997-07-31
AU695366B2 (en) 1998-08-13
PL321630A1 (en) 1997-12-08
EE03384B1 (et) 2001-04-16
CN1083263C (zh) 2002-04-24

Similar Documents

Publication Publication Date Title
US11241429B2 (en) Method of treating metabolic disorders and depression with dopamine receptor agonists
LT3893B (en) Pharmaceutical composition with nalmefene for treating alcoholism
EP0724878B1 (en) Use of melatonin for treating patients suffering from drug dependencies
US20030008005A1 (en) Sublingual administration of dihydroergotamine for the treatment of migraine
BG62876B1 (bg) Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост
US5830895A (en) Methods for the determination and adjustment of prolactin daily rhythms
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
Dépôt et al. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans
Linnoila et al. How to antagonize ethanol-induced inebriation
CA2211839C (en) Use of melatonin for treating patients suffering from drug addiction
AU3101395A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
Wurtman Ramelteon: a melatonin receptor agonist
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro
Wasielewski Attenuation of alcohol-induced circadian phase-shifts using melatonin and vitamin B12